QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
NASDAQ:INCY

Incyte - INCY Stock Forecast, Price & News

$80.50
-0.46 (-0.57%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$79.45
$81.14
50-Day Range
$78.82
$86.01
52-Week Range
$65.07
$86.29
Volume
2.36 million shs
Average Volume
1.95 million shs
Market Capitalization
$17.91 billion
P/E Ratio
20.48
Dividend Yield
N/A
Price Target
$84.09

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
4.5% Upside
$84.09 Price Target
Short Interest
Healthy
1.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.19mentions of Incyte in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$9.45 M Sold Last Quarter
Proj. Earnings Growth
58.96%
From $2.12 to $3.37 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

37th out of 1,026 stocks

Commercial Physical Research Industry

1st out of 17 stocks

INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

Markets Rise on Powell's Inflation Comments
Putin's boneheaded mistake could make Americans INCREDIBLY RICH!
The mainstream media isn't talking about this, but Americans who catch on early to this mistake made by Vladimir Putin... could become wealthy. This will be sure to infuriate him! Click here to see how. pixel
Incyte (INCY) Set to Announce Quarterly Earnings on Tuesday
Incyte Co. (NASDAQ:INCY) EVP Sells $5,086,433.76 in Stock
5 Hypergrowth Stocks to Own in 2023
Luke Lango has found 14 stocks that have gone up over 1,000% - now he’s naming his top stocks for 2023 in a new free report. Just click below to claim your copy today. pixel
Piper Sandler Begins Coverage on Incyte (NASDAQ:INCY)
How Incyte's Alapocas campus could expand
Incyte: Opzelura Is The Main Growth Driver
Incyte: Making Hay While The Sun Shines
Incyte Gets a Quantitative Upgrade
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
Incyte A Buy As Revenue From Opzelura Ramps
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings
2/07/2023
Today
2/08/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,094
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$84.09
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+4.5%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

Net Income
$948.58 million
Pretax Margin
17.07%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$2.27 per share
Book Value
$17.07 per share

Miscellaneous

Free Float
183,542,000
Market Cap
$17.91 billion
Optionable
Optionable
Beta
0.73

Social Links


Key Executives

  • Herve HoppenotHerve Hoppenot
    Chairman, President & Chief Executive Officer
  • Christiana Stamoulis
    Chief Financial Officer & Executive Vice President
  • Steven H. SteinSteven H. Stein
    Chief Medical Officer & Executive Vice President
  • Dashyant DhanakDashyant Dhanak
    Chief Scientific Officer & Executive VP
  • Barry FlannellyBarry Flannelly
    EVP & General Manager-North America













INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2023?

10 Wall Street analysts have issued twelve-month price objectives for Incyte's shares. Their INCY share price forecasts range from $63.00 to $100.00. On average, they expect the company's stock price to reach $84.09 in the next year. This suggests a possible upside of 4.5% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2023?

Incyte's stock was trading at $80.32 at the beginning of 2023. Since then, INCY stock has increased by 0.2% and is now trading at $80.50.
View the best growth stocks for 2023 here
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) issued its quarterly earnings data on Tuesday, February, 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.59 by $0.03. The biopharmaceutical company earned $926.70 million during the quarter, compared to analysts' expectations of $880.25 million. Incyte had a net margin of 26.30% and a trailing twelve-month return on equity of 9.04%. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.07) EPS.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by many different institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.56%), LSV Asset Management (0.54%), Assenagon Asset Management S.A. (0.50%), ARK Investment Management LLC (0.43%), Swiss National Bank (0.35%) and Sumitomo Mitsui Trust Holdings Inc. (0.34%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $80.50.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $17.91 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $3.93 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,094 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 2/8/2023 by MarketBeat.com Staff